BiotechTube

Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified)

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Exercise-induced Bronchoconstriction (EIB)

Conditions

Exercise-induced Bronchoconstriction (EIB)

Trial Timeline

Feb 1, 2008 → Mar 1, 2010

NCT ID
NCT00534976

About Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified)

Comparator: montelukast sodium + Comparator: Comparator: placebo (unspecified) is a approved stage product being developed by Organon for Exercise-induced Bronchoconstriction (EIB). The current trial status is completed. This product is registered under clinical trial identifier NCT00534976. Target conditions include Exercise-induced Bronchoconstriction (EIB).

What happened to similar drugs?

1 of 7 similar drugs in Exercise-induced Bronchoconstriction (EIB) were approved

Approved (1) Terminated (0) Active (6)
🔄Levalbuterol tartrate HFA MDI + PlaceboSumitomo PharmaPhase 3
🔄Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhalerAstraZenecaPhase 3
🔄BenralizumabAstraZenecaPhase 3
✅AmbrisentanGilead SciencesApproved
🔄Comparator: Montelukast + Comparator: PlaceboOrganonPhase 3
🔄Comparator: Montelukast + Comparator: PlaceboOrganonPhase 3
🔄Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)OrganonPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00534976ApprovedCompleted

Competing Products

10 competing products in Exercise-induced Bronchoconstriction (EIB)

See all competitors
ProductCompanyStageHype Score
Levalbuterol tartrate HFA MDI + PlaceboSumitomo PharmaPhase 3
40
Budesonide/albuterol metered-dose inhaler 160/180 μg + Placebo metered-dose inhalerAstraZenecaPhase 3
40
BenralizumabAstraZenecaPhase 3
36
Administration of montelukast or placeboMerckPre-clinical
18
AmbrisentanGilead SciencesApproved
43
Combination DSCG and ReproterolSanofiPhase 2
35
Comparator: Montelukast + Comparator: PlaceboOrganonPhase 3
34
Comparator: Montelukast + Comparator: PlaceboOrganonPhase 3
34
montelukast sodium + Comparator: placebo (unspecified)OrganonPhase 1
23
Comparator: Montelukast + Comparator: Salmeterol + Comparator: Placebo (montelukast) + Comparator: Placebo (salmeterol)OrganonPhase 3
34